OZ
OZYMF.US Orphazyme A/S
- Market cap
- USD 4.84M
- P/E
- -
- P/B
- 0.35x
- ROE
- 21.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is OZYMF.US undervalued?
Graham numberThe Graham number of Orphazyme A/S cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Orphazyme A/S fundamental analysis
No fundamental analysis for Orphazyme A/S yet.
Orphazyme A/S stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Orphazyme A/S
Strategic Partners A/S does not have significant operations. Previously, it was engaged in biotech activities. The company was formerly known as Orphazyme A/S and changed its name to Strategic Partners A/S in October 2024. Strategic Partners A/S was incorporated in 2009 and is based in Herlev, Denmark.
Full company profileOrphazyme A/S financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Orphazyme A/S annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 36.2M | - | 0.00 | 0.00 | 309K | 399K |
| Gross Profit | -572K | -746K | -1.37M | -3.80M | -5.20M | 18.1M | -782K | - | - | 309K | - |
| Operating Income | -63.5M | -131M | -232M | -336M | -609M | -83.5M | -41.2M | -27.0M | -201.00 | -2.45M | -3.69M |
| EBITDA | -62.8M | -130M | -230M | -334M | -616M | -604M | -40.4M | 769K | 201K | -2.45M | -3.69M |
| Net Income | -57.9M | -126M | -230M | -337M | -633M | -627M | -111M | -26.0M | -298.00 | -859K | 4.06M |
| EPS | -5.65 | -10 | -11 | -17 | -22 | -18 | -3.14 | -0.74 | 0.00 | -21 | 97 |
| Balance Sheet | |||||||||||
| Total Assets | 31.9M | 663M | 441M | 181M | 822M | 173M | 56.8M | 19.3M | 23.6M | 19.5M | 20.0M |
| Total Liabilities | 14.4M | 47.1M | 53.1M | 128M | 202M | 164M | 15.9M | 5.07M | 4.31M | 1.15M | 699K |
| Shareholders' Equity | 17.5M | 616M | 388M | 53.0M | 621M | 9.34M | 41.0M | 14.2M | 19.2M | 18.4M | 19.3M |
| Cash & Short-term Investments | 14.3M | 632M | 395M | 124M | 727M | 102M | 38.9M | 18.2M | 20.0M | 15.9M | 16.5M |
| Total Debt | - | - | - | 77.1M | 70.7M | 40.0M | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -54.7M | -95.4M | -235M | -327M | -539M | -603M | -118K | -20.0M | -3.36M | -2.13M | -5.34M |
| Capital Expenditure | 238K | 1.49M | 2.35M | 3.29M | 5.10M | 994K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -55.0M | -96.9M | -237M | -330M | -544M | -604M | -118K | -20.0K | -3.36M | -2.13M | -5.34M |
| Ratios | |||||||||||
| ROE | -330.9% | -20.5% | -59.1% | -637.2% | -102.1% | -6,708.8% | -269.9% | -182.9% | 0.0% | -4.7% | 21.0% |
| ROA | -181.4% | -19.0% | -52.0% | -186.7% | -77.0% | -361.7% | -194.6% | -134.9% | 0.0% | -4.4% | 20.3% |
| Net Profit Margin | - | - | - | - | - | -1,731.1% | - | - | - | -278.0% | 1,019.0% |
| Debt to Equity | - | - | - | 1.46x | 0.11x | 4.28x | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Orphazyme A/S dividends
Orphazyme A/S has not paid dividends in the last 9 fiscal years.
Last stock split: 1:1000 on Dec 6, 2023.
Who owns Orphazyme A/S
- Insiders 68.93%
- Institutions 4.49%
- Public & others 26.59%
- Shares outstanding 53.7K
- Free float 1.99K
Orphazyme A/S company profile
- Company name
- Orphazyme A/S
- Ticker
- OZYMF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1
- Fiscal year end
- December
- Address
- Lyskær 8A, Herlev, Denmark, 2730
- Phone
- 45 28 12 66 09
- Website
- strategic-partners.dk
About Orphazyme A/S
Strategic Partners A/S does not have significant operations. Previously, it was engaged in biotech activities. The company was formerly known as Orphazyme A/S and changed its name to Strategic Partners A/S in October 2024. Strategic Partners A/S was incorporated in 2009 and is based in Herlev, Denmark.
Orphazyme A/S management
1- Mr. Jakob Færch BendtsenCEO & Director · born 1978